Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial

What Was Tested

The paper reports a study of Leuprolide and Triptorelin in the context of endometriosis, published as a randomized controlled trial.

To compare two postoperative treatments: Dienogest and GnRH agonists.

Why It Was Studied

The recurrence of deep infiltrating endometriosis (DIE) after its surgical excision is a big problem: postoperative treatment is crucial.

Who Took Part

According to the abstract, 146 women were involved.

PubMed tags the participants as women only.

146 women submitted to laparoscopic eradication of DIE with bowel and parametrial surgery.

Patients were randomized into two groups.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Prospective Randomized Controlled Trial (RCT).

A second interview at 30 ± 6 months valued pain relapse, imaging relapse, and pregnancy rate.

What Was Measured

PubMed files the paper under topics including Endometriosis, Gonadotropin-Releasing Hormone, Intestines, Laparoscopy, Leuprolide, Nandrolone and Pelvic Pain.

The authors tagged it with the keywords Dienogest and deep infiltrating endometriosis.

What This Means in Plain Language

The paper is a randomized study of Leuprolide and Triptorelin in 146 women in people with endometriosis.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology), a journal based in England.

More context: the Leuprolide compound page and the Triptorelin compound page, Endometriosis research.